SOLIGENIX, INC. Operating Lease, Expense
SOLIGENIX, INC. (SNGX) reported Operating Lease, Expense of $33.33 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2021-05-18
- SOLIGENIX, INC. operating lease, expense for the quarter ending 2021-03-31 was $33.33K, a 5.59% decline year-over-year.
- SOLIGENIX, INC. operating lease, expense for the quarter ending 2020-03-31 was $35.30K, a 0.00% change year-over-year.
- SOLIGENIX, INC. operating lease, expense for the quarter ending 2019-12-31 was $35.30K.
- SOLIGENIX, INC. operating lease, expense for the quarter ending 2019-09-30 was $35.30K.
- SOLIGENIX, INC. operating lease, expense for fiscal 2020 was $139.88K, a 0.93% decline from fiscal 2019.
- SOLIGENIX, INC. operating lease, expense for fiscal 2019 was $141.19K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2021-03-31 | $33.33K 10-Q · filed 2021-05-18 | |||
| 2020-12-31 | $139.88K 10-K · filed 2021-03-30 | |||
| 2020-03-31 | $35.30K 10-Q · filed 2020-05-15 | $70.60K derived: sum of 2 quarters · filed 2021-03-30 | $105.89K derived: sum of 3 quarters · filed 2021-03-30 | $141.19K derived: sum of 4 quarters · filed 2021-03-30 |
| 2019-12-31 | $35.30K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $70.60K derived: sum of 2 quarters · filed 2021-03-30 | $105.89K derived: sum of 3 quarters · filed 2021-03-30 | $141.19K 10-K · filed 2021-03-30 |
| 2019-09-30 | $35.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $70.59K derived: sum of 2 quarters · filed 2019-11-12 | $105.89K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $35.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $70.59K 10-Q · filed 2019-08-13 | ||
| 2019-03-31 | $35.30K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |